Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2025 (Events reported through May 27, 2025)
Reporting Period: The filing covers material definitive agreements and unregistered sales of equity securities executed in May 2025.
Key Financial Metrics and Capital Structure
The filing details specific capital raising activities and debt modifications rather than standard operating financial metrics (revenue, profit, cash flow).
- Equity Raised: $116,249 received from two accredited investors via unit subscriptions.
- Debt Instrument: $500,000 principal amount on an Amended and Restated Convertible Promissory Note (A&R Note) with Indigo Capital LP.
- Debt Terms: 18% annual interest, compounded monthly; maturity date April 15, 2026.
- Service Compensation: Issuance of 120,000 restricted shares to Levo Healthcare Consulting, Inc. for marketing services, plus monthly fees of $25,000–$35,000 and a 4% revenue share.
Material Changes and Agreements
Unit Subscription Agreement
On May 23, 2025, the Company sold 70,454 units at $1.65 per unit. Each unit consists of one share of common stock and one-half of one warrant.
- Shares Issued: 70,454 shares of common stock.
- Warrants Issued: Warrants to purchase 35,227 shares.
- Warrant Terms: Exercise price of $3.00; expiration May 23, 2028; includes a 4.999% beneficial ownership limitation.
- Acceleration Clause: Warrants may be accelerated to expire if the VWAP of common stock reaches or exceeds $3.00 for five consecutive trading days.
Amended and Restated Convertible Promissory Note
On May 27, 2025, the Company amended a $500,000 note originally issued on April 15, 2025, to Indigo Capital LP.
- Conversion Rights: Holder may convert principal and accrued interest into common stock at $1.50 per share (subject to 4.999% beneficial ownership limitation).
- Prepayment Change: The "Mandatory Prepayment" requirement upon a Qualified Financing was removed.
- Additional Warrants: Holder granted warrants to purchase 275,482 shares at an exercise price of $1.815, expiring May 27, 2028.
Marketing Services Agreement
On May 15, 2025, the Company entered a 36-month agreement with Levo Healthcare Consulting, Inc., effective June 1, 2025.
- Equity Compensation: 120,000 restricted shares issued immediately, vesting at 10,000 shares per month.
- Cash Compensation: Monthly media buying fees ($25,000–$35,000) plus 4% of gross revenue generated by services.
- Exclusivity: Company must exclusively use Levo for marketing, creative, development, lifestyle, and analytics.
Outlook, Risks, and Contingencies
Dilution Risk: The filing outlines significant potential dilution if warrants are exercised or the note is converted:
- Investor Warrants: Up to 35,227 shares.
- Holder Warrants: Up to 275,482 shares.
- Note Conversion: Up to 333,333 shares (principal only, excluding accrued interest).
Beneficial Ownership Limitations: Both the Investor Warrants and Holder Warrants contain a 4.999% beneficial ownership limitation, which may be increased to 9.999% with 61 days' prior written notice.
Regulatory Status: All securities were issued pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D exemptions, involving no public offering or underwriters.
Investor Verification Checklist
- Verify the current outstanding share count to assess the immediate dilution impact of the 70,454 shares issued and the 120,000 shares issued to Levo.
- Confirm the Company's ability to service the $500,000 debt obligation at 18% interest or the likelihood of conversion at $1.50 per share.
- Review the "Qualified Financing" definition in the A&R Note to understand future fundraising constraints.
- Monitor the stock price relative to the $3.00 acceleration trigger for Investor Warrants and the $1.815 exercise price for Holder Warrants.
- Assess the financial impact of the exclusive marketing agreement, specifically the variable 4% revenue share and monthly fees.